Sucampo Pharmaceuticals, Inc (ticker: SCMP, exchange: NASDAQ Global Market (.O))
News Release -
Sucampo Appoints Cary J. Claiborne as Chief Financial Officer
BETHESDA, Md., Oct 27, 2011 (BUSINESS WIRE) --
Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) today announced the
appointment of Cary
J. Claiborne as SPI's Chief Financial Officer (CFO), effective
immediately, reporting to Ryuji Ueno, M.D., Ph.D., Ph.D., Chairman and
Chief Executive Officer (CEO), and James J. Egan, Chief Operating
Officer, of SPI. Mr. Claiborne has been Sucampo's Interim CFO since
"I am very pleased that Cary Claiborne has joined Sucampo as our CFO.
His experience has already benefited us as we prepare for a major
inflection point in our history," said Ryuji
Ueno, M.D., Ph.D., Ph.D., Chairman and CEO of SPI. "I believe he
will help bring Sucampo to the next level."
Mr. Claiborne brings to Sucampo more than 25 years of financial
expertise and senior leadership experience in both publicly traded and
privately-held companies. Before his appointment in March 2011 as SPI's
Interim CFO, Mr. Claiborne had been President, CEO, and a member of the
board of directors of New Generation Biofuels, Inc., of Columbia,
Maryland, a publicly traded biofuel technology company, as well as its
CFO. While at New Generation, Mr. Claiborne organized and led that
company's finance and administrative functions, including Treasury,
Human Resources, Business Development, Legal, Strategic Planning,
Intellectual Property and IT. Prior to joining New Generation in 2007,
Mr. Claiborne had been CFO of Osiris Therapeutics, Inc., a stem cell
therapeutics company, since 2004. During his tenure there, he led that
company through its Initial Public Offering of shares, transforming it
from a privately held company to one listed on NASDAQ, which included
developing and implementing corporate governance policies and
procedures, an SEC financial reporting process and working capital/cost
control procedures. Mr. Claiborne began his career at General Electric
Company, in 1982, and held a series of progressively more responsible
positions in financial management and senior management, including
President and CEO of New Enterprise Wholesale Services at GE Capital.
Mr. Claiborne joined MCI Corporation where he was VP-Financial Planning
& Analysis in 1997, and The Home Depot, Inc., where he was VP-Financial
Planning & Analysis in 2000. Mr. Claiborne graduated from Rutgers
University where he earned a BA, Business Administration and earned
an MBA, in Finance, from Villanova
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc., an international pharmaceutical company,
focuses on the development and commercialization of medicines based on prostones.
The therapeutic potential of prostones, which occur naturally in the
human body as a result of enzymatic (15-PGDH) transformation of certain
fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D.,
Sucampo Pharmaceuticals' Chairman and CEO. Dr. Ueno founded Sucampo
Pharmaceuticals in 1996 with Sachiko
Kuno, Ph.D., founding CEO and currently Executive Advisor,
International Business Development and a member of the Board of
Directors. For more information about Sucampo Pharmaceuticals, please
AMITIZA is a registered trademark of Sucampo Pharmaceuticals, Inc.
RESCULA is a registered trademark of R-Tech Ueno, ltd., and has been
licensed to Sucampo Pharmaceuticals, Inc.
Any statements in this press release about future expectations, plans
and prospects for Sucampo Pharmaceuticals are forward-looking statements
made under the provisions of The Private Securities Litigation Reform
Act of 1995. Forward-looking statements may be identified by the words
"project," "believe," "anticipate," "plan," "expect," "estimate,"
"intend," "should," "would," "could," "will," "may" or other similar
expressions. Forward-looking statements include statements about the
potential utility of AMITIZA(R) and RESCULA(R) to
treat particular indications and expected data availability dates.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including those described in Sucampo Pharmaceuticals' filings with the
Securities and Exchange Commission (SEC), including the annual report on
Form 10-K for the year ended December 31, 2010 and other periodic
reports filed with the SEC. Any forward-looking statements in this press
release represent Sucampo Pharmaceuticals' views only as of the date of
this release and should not be relied upon as representing its views as
of any subsequent date. Sucampo Pharmaceuticals anticipates that
subsequent events and developments will cause its views to change.
However, while Sucampo Pharmaceuticals may elect to update these
forward-looking statements publicly at some point in the future, Sucampo
Pharmaceuticals specifically disclaims any obligation to do so, whether
as a result of new information, future events or otherwise.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50045346&lang=en
SOURCE: Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.
Kate de Santis, 240-223-3834